FDA recalls ADHD medications
ST. JOSPEH, Mo. (KQTV) -- A heavily used Attention Deficit Hyperactivity Disorder (ADHD) medication is being recalled because users aren't able to get the full effect.
Lisdexamfetamine Dimesylate Capsules, the generic form of Vyvanse, is being recalled, according to the Food and Drug Administration.
The recall was announced on Oct. 28 for the capsule, which is already in short supply.
The Board of Pharmacy said the recall involves several medicine dosages, such as 10 mg, 20 mg, 30 mg, 40 mg, 50 mg, 60 mg and 70 mg.
According to the Board, the recall was initiated in response to out-of-specification (OOS) results observed in the product's dissolution test for the 60 mg capsules in Batch AD50896.
Based on the Health Hazard Evaluation, "Dissolution is important for drugs to be absorbed and have a physiological effect on the human body, they must be in solution. The impacted capsule would not be able to deliver optimal level of medicine and may impact therapeutic efficacy of the product."
Sun Pharmaceutical Industries, Inc. initiated the shipment of the product between May 1, 2024, and Nov. 13, 2024. Each lot in the shipments contained 100-count bottles.
According to a study done by the Children's Hospital of Philadelphia, there has been an increase in ADHD diagnoses due to increased awareness.
The Centers for Disease Control and Prevention (CDC) reports that between 2020 and 2023, 10% of children ages 3 through 17 were diagnosed with ADHD in the state of Missouri.
The same CDC report also shows a total of 70.2% of Missourians were treated with the disorder between 2020 and 2023.
Patients who have and are currently taking the recalled medication have been encouraged to contact their doctor or pharmacy for replacement or refunds.
